The best name in the room is worthless if it conflicts.
Pharmaceutical naming for products, companies and platforms: a naming process that generates real candidates and screens them against trademark and regulatory naming conflicts before anyone gets attached to one.
Naming in this sector fails less often on creativity than on process: a name the team loves gets presented, gets attached to, and then fails a trademark or regulatory naming-similarity check months later. Screening early, not last, is what makes a naming project actually land.
A naming brief and territory exploration, a shortlist of genuinely distinct candidates, preliminary screening coordinated with your legal counsel, and a final recommendation with the reasoning documented.
We coordinate closely with your legal and regulatory counsel, who run the formal trademark and INN clearance, and we generate names informed by what typically fails it, so the shortlist you screen is already shaped to clear, not just to sound good.
The scope our pharmaceutical naming work has operated within.
A drug name, a company name and a platform name are governed by different rules. Pharmaceutical naming starts from what is being named.
What comes up before starting a naming project.
No, formal clearance always runs through your legal counsel, not through us. We do preliminary screening ourselves to filter out obvious conflicts before the shortlist is presented, which reduces how much of your legal budget gets spent on screening names that were never realistically going to survive review anyway.
Drug product names face regulatory naming-similarity review from health authorities on top of the usual trademark conflict check, a narrower space than company or platform naming has to work within. That extra constraint changes the whole generation approach, from how broad the first list runs to how early screening starts.
Enough for a real choice without diluting quality, which usually means a handful of distinct directions rather than a long list padded with filler options no one would choose. Each shortlisted name gets preliminary screening before it reaches you, so every option is one you could use.
Yes, and for multi-market products that screening is essential rather than optional. Checking connotation, pronunciation and unintended meaning across your target markets happens during the screening stage itself, before a name is presented, not as a check applied after one has already been chosen and grown attached to internally.
Naming usually precedes brand identity and rollout work. These are the related services.
A new product, company or platform that needs a name. Tell us what is being named and we will tell you how we would approach the pharmaceutical naming.